LIPOSOMAL AMPHOTERICIN-B IN NEONATES WITH INVASIVE CANDIDIASIS

Liposomal amphotericin B L-Amp B, a novel formulation of Amp B, is eff ective for the treatment of invasive fungal infections in children and adults and is associated with less toxicity than the conventional pre paration. Data on the use of L-Amp fi in neonates is scarce. We descri be the clinical course of two premature infants who were treated with L-Amp B (one infant had candidemia, and the other had candidemia and m eningitis), and provide a summary of previously published experience o n this topic. L-Amp B may be an option for therapy of invasive candidi asis in neonates who are at high risk of nephrotoxicity and other amph otericin-related reactions, but clinical trials are necessary to docum ent its safety and efficacy in this age group.